logo-loader
viewSkinBioTherapeutics PLC

SkinBioTherapeutics teams up with Winclove Probiotics for psoriasis supplement

SkinBioTherapeutics PLC's (LON:SBTX) Stuart Ashman caught up with Proactive London's Andrew Scott following the news they've agreed a deal with Dutch firm Winclove Probiotics to develop a food supplement to combat psoriasis.

The pair plan to carry out a human study on mild to moderate sufferers of the skin condition, which will take between 12 and 18 months ahead of commercialisation and launch of the probiotic.

Quick facts: SkinBioTherapeutics PLC

Price: 6.3 GBX

AIM:SBTX
Market: AIM
Market Cap: £8.07 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of SkinBioTherapeutics PLC named herein, including the promotion by the Company of SkinBioTherapeutics PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Morning Report: Crispin Odey wades into Sirius Minerals takeover battle

Headlines from the Proactive UK newsroom. Crispin Odey has slammed the proposed takeover of Sirius Minerals (LON:SXX) by Anglo American. His hedge fund, Odey Asset Management, has declared a 1.29% stake in the potash group and says the 5.5p per share offer is not fair and should not have been...

on 19/2/20

2 min read